Year To Quarter End Statement Of Income

ASKA Pharmaceutical Holdings CO., Ltd. - Filing #7608021

Concept 2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
2021-04-01 to
2021-06-30
Year to quarter end statement of income
Statement of income
Net sales
1,394,000,000 JPY
14,234,000,000 JPY
-12,000,000 JPY
12,840,000,000 JPY
14,221,000,000 JPY
Cost of sales
7,531,000,000 JPY
Gross profit (loss)
6,690,000,000 JPY
Selling, general and administrative expenses
5,501,000,000 JPY
Selling, general and administrative expenses
Operating profit (loss)
100,000,000 JPY
1,348,000,000 JPY
-160,000,000 JPY
1,247,000,000 JPY
1,188,000,000 JPY
Non-operating income
Interest income
0 JPY
Dividend income
130,000,000 JPY
Non-operating income
234,000,000 JPY
Non-operating expenses
Interest expenses
14,000,000 JPY
Non-operating expenses
92,000,000 JPY
Ordinary profit (loss)
1,329,000,000 JPY
Profit (loss) before income taxes
1,329,000,000 JPY
Income taxes - current
165,000,000 JPY
Income taxes - deferred
65,000,000 JPY
Income taxes
230,000,000 JPY
Profit (loss)
1,098,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.